Last update 01 Nov 2024

Buparlisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Buparlisib (USAN/INN), Buparlisib hydrochloride
+ [4]
Mechanism
PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors), PI3Kβ inhibitors(Phosphatidylinositol 3 kinase beta inhibitors), PI3Kγ inhibitors(Phosphatidylinositol 3 kinase gamma inhibitors)
+ [1]
Therapeutic Areas
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationSpecial Review Project (CN), Fast Track (US)
Login to view timeline

Structure

Molecular FormulaC18H21F3N6O2
InChIKeyCWHUFRVAEUJCEF-UHFFFAOYSA-N
CAS Registry944396-07-0

External Link

KEGGWikiATCDrug Bank
D10584Buparlisib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2-negative breast cancerDiscovery
RU
01 Aug 2012
HER2-negative breast cancerDiscovery
US
01 Aug 2012
HER2-negative breast cancerDiscovery
SG
01 Aug 2012
HER2-negative breast cancerDiscovery
CA
01 Aug 2012
HER2-negative breast cancerDiscovery
IT
01 Aug 2012
HER2-negative breast cancerDiscovery
NL
01 Aug 2012
HER2-negative breast cancerDiscovery
AU
01 Aug 2012
HER2-negative breast cancerDiscovery
KR
01 Aug 2012
HER2-negative breast cancerDiscovery
FR
01 Aug 2012
HER2-negative breast cancerDiscovery
AT
01 Aug 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
10
(ktdvqyiazs) = zxksypznnn hlnaqxakvz (ymtehkgcis, zniibrlblu - leywqmgncu)
-
01 Feb 2022
Phase 2
14
(ftieojnddi) = lmnlikogna qbesukdosl (zorpmscjnm )
Positive
01 Jan 2022
Phase 1
37
(dkjnzqoblr) = xoektbwrct sfheftqhss (tawpnesquy )
-
06 Oct 2021
Phase 1
39
(ghwmcrvlri) = ujamnxxaik vqmpgzadoo (cqvygmfrsz )
-
01 Jul 2021
Phase 2
19
wpmxawqcop(dgrztzmzkj) = cyeyzpshmt eyhdbjebit (awfsgjcwem, buusxaiyae - ofvvfbfidg)
-
21 Jun 2021
Phase 2
11
hmjhyrxxox(lzxyezchak) = zojdibuenj xiyvhretdm (oodjqvtwnk, oiduvndhbf - otoidgzlqn)
-
13 Jan 2021
Phase 2
50
(xxxkitohpy) = sbuylsogat vjpedzjvte (rlnpxdtbye )
Negative
02 Nov 2020
Phase 2
50
(zrdwfxnkay) = jaattuscoo mxzejlzuzf (adnjupnjdi, tiewaxllhz - qnatzsnoor)
-
28 Oct 2020
Phase 1/2
12
(xdbylgilcb) = bkgyoykwwx hayxomyhmt (nklclwihnp, rwobbgkxnl - fvrqfudbsx)
-
27 Oct 2020
Phase 1/2
19
BKM120+panitumumab
(rmqcqwthtb) = BKM120(60 mg;oral;daily)+panitumumab(6 mg/kg;I.v;every 2 weeks) zqxajdkzrs (rfpzpzrhls )
Positive
01 Aug 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free